All posts tagged antonio jimeno

  • Photos taken on the Anschutz Medical Campus University of Colorado Denver in Aurora.   (Photo by Glenn Asakawa/University of Colorado)

    AACR News: Rigosertib Phase 1 results lead to disease-focused Phase 2 development

    Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug candidate is being developed by Onconova Therapeutics, Inc., of Pennington, NJ.

Tim Elliott, Lynn Clark Photography
Paul and Karen Wehling
HPV Vaccine recommended for boys
Antonio Jimeno, MD, PhD, investigator at the University of Colorado Cancer Center
Grogam Family, University of Colorado Cancer Center
Pat & Myka Landry, CU Cancer Center patient and caregiver.
Rahool and Kuntal Vora
Dr. Antonio Jimeno with patient Katrina, who is doing well on an anti-stem cell treatment